黏菌素与黏菌素联合磷霉素治疗耐碳青霉烯类鲍曼不动杆菌感染的初步研究
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.
作者信息
Sirijatuphat Rujipas, Thamlikitkul Visanu
机构信息
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
出版信息
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601. doi: 10.1128/AAC.02435-13. Epub 2014 Jun 30.
Abstract
Ninety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.).
摘要
94例感染耐碳青霉烯鲍曼不动杆菌的患者被随机分组，分别接受单独使用黏菌素或黏菌素联合磷霉素治疗7至14天。与单独接受黏菌素治疗的患者相比，接受联合治疗的患者有显著更有利的微生物学反应，且在临床结局改善和死亡率降低方面有一定趋势。（本研究已在ClinicalTrials.gov注册，注册号为NCT01297894。）
相似文献
1
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601. doi: 10.1128/AAC.02435-13. Epub 2014 Jun 30.
2
Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
Int J Antimicrob Agents. 2024 Jul;64(1):107190. doi: 10.1016/j.ijantimicag.2024.107190. Epub 2024 Apr 30.
3
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.
4
Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Int J Antimicrob Agents. 2008 Sep;32(3):281-4. doi: 10.1016/j.ijantimicag.2008.04.013. Epub 2008 Jul 22.
5
Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
J Infect Dev Ctries. 2015 May 18;9(5):476-85. doi: 10.3855/jidc.6195.
6
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
7
Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.
8
The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Int J Infect Dis. 2020 Aug;97:391-395. doi: 10.1016/j.ijid.2020.05.100. Epub 2020 Jun 2.
9
Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Epidemiol Infect. 2013 Jun;141(6):1214-22. doi: 10.1017/S095026881200194X. Epub 2012 Sep 7.
10
Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
Chemotherapy. 2013;59(3):225-31. doi: 10.1159/000356004. Epub 2013 Dec 13.
引用本文的文献
1
activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant .
Microbiol Spectr. 2025 Sep 2;13(9):e0137925. doi: 10.1128/spectrum.01379-25. Epub 2025 Aug 12.
2
In Vitro Evaluation of Antimicrobial Synergy Against Multidrug-Resistant Gram-Negative Paediatric Bloodstream Pathogens in South Africa.
Antibiotics (Basel). 2025 Jun 20;14(7):630. doi: 10.3390/antibiotics14070630.
3
Assessing FilmArray Pneumonia+ panel dynamics during antibiotic treatment to predict clinical success in ICU patients with ventilated hospital-acquired pneumonia and ventilator-associated pneumonia: a multicenter prospective study.
Crit Care. 2025 Jul 12;29(1):301. doi: 10.1186/s13054-025-05503-7.
4
Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): a narrative review.
Eur J Clin Pharmacol. 2025 Jun 12. doi: 10.1007/s00228-025-03866-y.
5
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
6
Investigation of the Effects of Fosfomycin in Kidney Damage Caused by CLP-Induced Sepsis.
Life (Basel). 2024 Dec 24;15(1):2. doi: 10.3390/life15010002.
7
Carbapenem-resistant and Ventilator-associated Pneumonia; Epidemiology, Risk Factors, and Current Therapeutic Approaches.
J Res Pharm Pract. 2024 Dec 23;13(2):33-40. doi: 10.4103/jrpp.jrpp_50_24. eCollection 2024 Apr-Jun.
8
Multidrug resistant : A study on its pathogenesis and therapeutics.
Curr Res Microb Sci. 2024 Dec 6;8:100331. doi: 10.1016/j.crmicr.2024.100331. eCollection 2025.
9
Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Infections.
Pathogens. 2024 Nov 28;13(12):1049. doi: 10.3390/pathogens13121049.
10
Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.
Syst Rev. 2024 Dec 19;13(1):309. doi: 10.1186/s13643-024-02695-x.
本文引用的文献
1
High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1409-17. doi: 10.1164/rccm.201102-0349OC. Epub 2011 Sep 15.
2
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94. doi: 10.1128/AAC.01733-10. Epub 2011 May 9.
3
Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
Chest. 2010 Dec;138(6):1333-9. doi: 10.1378/chest.10-0463. Epub 2010 Jun 17.
4
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28.
5
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.
Clin Microbiol Infect. 2008 Sep;14(9):816-27. doi: 10.1111/j.1469-0691.2008.02061.x.
6
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
Clin Infect Dis. 2008 Apr 1;46(7):1069-77. doi: 10.1086/527442.
7
Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic therapy.
J Crit Care. 2008 Mar;23(1):34-40. doi: 10.1016/j.jcrc.2007.12.015.
8
Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
Int J Infect Dis. 2007 Sep;11(5):402-6. doi: 10.1016/j.ijid.2006.09.011. Epub 2007 Feb 8.
9
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
Crit Care. 2004 Aug;8(4):R204-12. doi: 10.1186/cc2872. Epub 2004 May 24.
10
Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.
Antimicrob Agents Chemother. 2000 Oct;44(10):2728-32. doi: 10.1128/AAC.44.10.2728-2732.2000.
Zotero 插件